Landmark Discovery of Ultra-Rare Blood Group Antigen CRIB in India

Chanchal Kumar Mazumder with inputs from Agencies, September 26, 2025 : Scientists in India have identified an ultra-rare blood group antigen called CRIB in a 38-year-old woman from Kolar, Karnataka. This groundbreaking discovery marks the first documentation of CRIB, a new antigen in the rare and complex Cromer blood group system, opening new avenues for transfusion medicine, organ transplantation, and immunogenetics. The patient’s blood was found incompatible with all known donor units, including standard O positive blood. After months of research conducted by the Rotary Bangalore TTK Blood Centre in collaboration with the UK’s International Blood Group Reference Laboratory (IBGRL), the findings were confirmed.

The Discovery of CRIB

The discovery of CRIB took place in July 2024, during a cardiac operation on a woman from Kolar, Karnataka. Despite being initially classified as having O-positive blood, her blood was incompatible with all known blood types, including O-positive donor blood. Even after collecting 20 samples from her family members, no match was found. With no external blood supply available, the medical team decided to proceed with the surgery, facing the risks of blood loss.

Miraculously, the surgery was completed successfully without the need for any transfusions. The patient recovered well, and her blood samples were sent to the IBGRL in the UK for further investigation. After ten months of detailed research, scientists confirmed that the woman's red blood cells contained an antigen previously unknown to medical science. This antigen was found to belong to the Cromer blood group system, and it was given the name CRIB, which stands for Cromer India Bengaluru—a tribute to its discovery in India, specifically in Bengaluru.

Clinical and Scientific Significance

The identification of CRIB challenges the current understanding of blood compatibility. The patient’s immune system rejects all known blood types due to the absence of the CRIB antigen. As a result, her blood is incompatible with almost all tested blood types, including O-positive, the universal blood type. This discovery not only redefines blood compatibility but also underscores the limitations of existing blood grouping systems.

Implications for Transfusion Medicine:

Enhanced Blood Compatibility: The discovery of CRIB opens up new possibilities in transfusion medicine. It emphasizes the necessity for ultra-rare blood donor panels and specialized antibody test kits to identify and address such anomalies.

Organ Transplantation:

Impact on Graft Compatibility: The uniqueness of the CRIB antigen could significantly affect organ transplant compatibility. Transplant teams will need to account for rare blood profiles like CRIB when assessing graft viability and immune rejection.

Genetic Diversity and Screening:

Molecular Screening: This finding highlights the importance of genetic blood typing and molecular diagnostics to identify rare blood groups, particularly in genetically diverse populations like India, where unusual variants are more likely to be found.

Global Recognition and Future Healthcare Implications

The significance of the CRIB discovery was officially recognized at the 35th Regional Congress of the International Society of Blood Transfusion (ISBT) held in Milan, Italy, in June 2025. This discovery is hailed as the first new blood group antigen incorporated into the Cromer system in decades.

Key Implications:

Rare Donor Registries: The Rotary Bangalore TTK Blood Centre, in partnership with the Karnataka State Blood Transfusion Council, has taken steps to establish a Rare Donor Registry. This will allow for the identification and management of rare blood types, improving healthcare readiness and ensuring the availability of compatible blood for patients like the woman from Kolar.
Improved Blood Typing and Diagnostics: The CRIB discovery calls for further investment in genetic blood typing and molecular diagnostics. It stresses the need for heightened awareness and training among healthcare professionals to better recognize atypical or panreactive blood cases, ensuring transfusion safety and reducing risks.
Impact on Pregnancy and Immune Reactions: Ongoing studies will explore how rare blood types like CRIB could affect pregnancy, hemolytic disease, and other immune-related conditions, expanding the scope of research in immunogenetics and maternal-fetal medicine.

The Patient's Journey and Medical Team's Dedication

Despite the challenges of her ultra-rare blood type, the woman underwent successful surgery without requiring a transfusion. The medical team, comprising hematologists and transfusion specialists, collaborated across continents to ensure the patient's survival and manage her blood incompatibility. Dr. Ankit Mathur, from Rotary Bangalore TTK Blood Centre, emphasized the importance of this discovery: “Her blood was panreactive to every sample tested. This discovery challenges the very foundation of existing transfusion science and opens new horizons for medicine.”

Looking Ahead: The Future of Blood Safety and Transfusion Medicine

The discovery of CRIB not only raises hope for patients with rare and unusual blood types but also reinforces the importance of continuous innovation in transfusion medicine and genetics. As medical science advances, it is crucial to invest in global rare blood donor registries, genetic screening, and education in transfusion safety. This case is a milestone moment that highlights India’s increasing contribution to the global medical community and opens new avenues for improving healthcare, donor matching, and surgical blood safety.

The discovery of the CRIB blood group is a remarkable milestone in transfusion medicine. It challenges existing blood grouping systems and sets the stage for advancements in genetic screening and rare donor registries. This groundbreaking finding not only offers new hope for patients with ultra-rare blood types but also provides critical insights that can shape the future of transfusion science, organ transplantation, and personalized medicine.